{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01954147",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SC/GLP-1"
      },
      "Organization": {
        "OrgFullName": "Diabetes Care Center of Nanjing Military Command",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus",
      "OfficialTitle": "Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2014",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2014",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2015",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 13, 2013",
      "StudyFirstSubmitQCDate": "September 26, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 1, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 19, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 20, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Diabetes Care Center of Nanjing Military Command",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Umbilical cord mesenchymal stem cells (SC) transplantation was a novel therapy for diabetes mellitus, with less side effects and more advantages. Clinical trials had verified that good metabolic control would be achieved when Liraglutide (GLP-1) was added to the conventional therapies. The investigators hypothesized that the combined therapy of umbilical cord mesenchymal stem cells transplantation and Liraglutide in type 2 diabetes mellitus will aid the differentiation of stem cells into insulin-producing cells, improve the survival of differentiated cells, protect the residual beta-cells and improve insulin secreting function, so as to achieve a favorable glucose homeostasis."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Type 2 Diabetes"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Factorial Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "100",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "SC-GLP-1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: GLP-1",
                "Biological: SC",
                "Other: Standard Medical Treatment"
              ]
            }
          },
          {
            "ArmGroupLabel": "SC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Umbilical Cord Mesenchymal Stem Cell Infusion",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: SC",
                "Other: Standard Medical Treatment"
              ]
            }
          },
          {
            "ArmGroupLabel": "GLP-1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Liraglutide",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: GLP-1",
                "Other: Standard Medical Treatment"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Standard Medical Treatment",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Standard Medical Treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "GLP-1",
            "InterventionDescription": "GLP-1 therapy",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "GLP-1",
                "SC-GLP-1"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "SC",
            "InterventionDescription": "Stem cell infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "SC",
                "SC-GLP-1"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Standard Medical Treatment",
            "InterventionDescription": "Standard Medical Treatment",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Control",
                "GLP-1",
                "SC",
                "SC-GLP-1"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "SMT"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "HbA1C",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Fasting Blood Glucose",
            "SecondaryOutcomeTimeFrame": "1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale and female patients age 35 to 65 years of age.\nAbility to provide written informed consent.\nMentally stable and able to comply with the procedures of the study protocol.\nClinical history compatible with type 2 diabetes (T2DM) as defined by ADA(1997) on the Diagnosis and classification of Diabetes Mellitus\nBasal C-peptide 0.5-2.0 ng/mL\nHbA1c ≥ 7.5 and ≤ 11% before standard medical therapy (SMT).\nPatients must have been treated with SMT for 1-4 months prior to matching. Insulin dose and metformin doses should be stable over 1 month prior to matching.\nHbA1c ≥ 7.5 and ≤ 10% at time of matching.\nTotal insulin daily dose (TDD) at time of matching should not exceed 1.0 units/day/kg\n18.5 kg/㎡≤BMI≤40.0kg/㎡\n\nExclusion Criteria:\n\nAbnormal liver function >2.5 x ULN\nEvidence of renal dysfunction:serum creatinine > 1.5 mg/dl (males) and 1.3 mg/dl (females).\nGastrointestinal operation history.\nType 1 Diabetes mellitus; DKA; secondary diabetes.\nUncontrolled blood Pressure: SBP >180 mmHg or DBP >100 mmHg at the time of matching.\nEvidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in past 6 months.\nPresence of active proliferative diabetic retinopathy or macular edema.\nAny acute or chronic infectious condition that in the criteria of the investigator would be a risk for the patient.\nFor female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. For male participants: intent to procreate 3 months before or after the intervention or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant?, Depo-Provera?, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.\nActive infection including hepatitis C, HIV, or TB as determined by a positive skin test or clinical presentation, or under treatment for suspected TB.\nSubjects that are being treated with any medication that could interfere with the outcome of the study such as: Thiazolidinediones and other glucagon like peptide 1 (GLP-1) analogues (Exenatide, Byetta), Pramlintide (Amylin), Dipeptidyl-peptidase IV (DPP-IV) inhibitors (i.e. Sitagliptin, Januvia)\nAny known or suspected allergy to liraglutide or other relevant products.\nEvidence of thyroid adverse events (serum calcitonin increase, goiter, thyroid cancer, et al) or pancreatitis caused by other GLP-1 analogues.\nSubjects with past history or family history of Medullary Thyroid Carcinoma(MTC) or Multiple Endocrine Neoplasia Syndrome Type 2(MEN2) .",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "35 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Xiangjin Xu, Professor",
            "OverallOfficialAffiliation": "Diabetes Care Center of Nanjing Millitary Command",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Diabetes Care Center of Nanjing Military Command",
            "LocationCity": "Fuzhou",
            "LocationState": "Fujian",
            "LocationZip": "350025",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "27143183",
            "ReferenceType": "derived",
            "ReferenceCitation": "Chen P, Huang Q, Xu XJ, Shao ZL, Huang LH, Yang XZ, Guo W, Li CM, Chen C. [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2016 May 1;55(5):349-54. doi: 10.3760/cma.j.issn.0578-1426.2016.05.004. Chinese."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003920",
            "ConditionMeshTerm": "Diabetes Mellitus"
          },
          {
            "ConditionMeshId": "D000003924",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 2"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafAsFound": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6271",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 2",
            "ConditionBrowseLeafAsFound": "Type 2 Diabetes",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M26150",
            "InterventionBrowseLeafName": "Glucagon-Like Peptide 1",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M419",
            "InterventionBrowseLeafName": "Liraglutide",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hypo",
            "InterventionBrowseBranchName": "Hypoglycemic Agents"
          }
        ]
      }
    }
  }
}